<DOC>
	<DOCNO>NCT01053520</DOCNO>
	<brief_summary>This Phase 1 , randomize , open-label , single center , three period crossover study determine oral bioavailability new ABT-263 formulation relative current ABT-263 formulation administer ongoing Phase 1/2a study . Approximately 12 healthy female subject enrol study .</brief_summary>
	<brief_title>Assess Oral Bioavailability New ABT-263 Formulation Healthy Female Subjects</brief_title>
	<detailed_description>This Phase 1 , randomize , open-label , single center , three period crossover study determine oral bioavailability new ABT-263 formulation relative current ABT-263 formulation administer ongoing Phase 1/2a study . Approximately 12 healthy female subject enrol study .</detailed_description>
	<mesh_term>Navitoclax</mesh_term>
	<criteria>Female age 18 55 year , inclusive . Must surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) , postmenopausal ( least 2 year ) , practice least one acceptable method birth control . Must negative result pregnancy test perform Screening urine sample obtain within 28 day prior initial study drug administration , Period 1 Day 1 serum specimen . Body Mass Index ( BMI ) 18 29 , inclusive . BMI calculate weight kg divide square height measure meter . Must adequate bone marrow function per local laboratory reference range ( Platelets &gt; /= low limit normal range , ANC &gt; /= low limit normal range ) A condition general good health , base upon result medical history , physical examination , vital sign , laboratory profile 12lead electrocardiogram ( ECG ) . Must voluntarily sign date inform consent , approve Independent Ethics Committee ( IEC ) /Institutional Review Board ( IRB ) , prior initiation studyspecific procedure . History significant sensitivity drug History drug alcohol abuse w/i 6 month currently receive Disulfiram Known/suspected history HIV History active medical condition ( ) surgical procedure ( ) might affect GI motility , pH , absorption History thrombocytopenic associate bleed w/i 1 year prior ABT263 Significant history cardiovascular disease ( e.g. , MI , thrombotic thromboembolic event last 6 month ) , renal , neurologic , psychiatric , endocrinologic , metabolic , immunologic , respiratory ( except mild asthma ) , gastrointestinal , hematologic , hepatic disease diabetes , cancer , epilepsy , seizures opinion PI would adversely affect participate study . Underlying condition predispose bleed currently exhibit sign clinically significant bleed active peptic ulcer disease hemorrhagic esophagitis/gastritis . Positive result drug abuse , alcohol , cotinine , hepatitis A virus immunoglobulin M ( HAVIgM ) , hepatitis B surface antigen ( HBsAg ) hepatitis C virus antibody ( HCV Ab ) . Consumed alcohol , grapefruit starfruit product , Seville oranges w/i 3 day prior ABT263 Received aspirin , anticoagulation therapy , drug herbal supplement affect platelet function w/i 7 day prior to/during ABT263 Used medication , vitamin , herbal supplement ( except contraceptive ) w/i 14 day prior ABT263 Received drug injection biologic agent w/i 30 day prior ABT263 ( except parenteral hormonal contraceptive ) Used know inhibitor inducer CYP3A w/i 1 month prior ABT263 ; Received investigational product w/i 6 week prior ABT263 Used tobacco nicotineproducts w/i 6 month prior ABT263 Pregnant breastfeed Donation loss &gt; /=550 mL blood receive transfusion blood product w/i 8 week prior ABT263 Currently enrol another study . The PI decide subject unsuitable receive ABT263 .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>